CN111989332A - 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 - Google Patents

作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN111989332A
CN111989332A CN201980022306.8A CN201980022306A CN111989332A CN 111989332 A CN111989332 A CN 111989332A CN 201980022306 A CN201980022306 A CN 201980022306A CN 111989332 A CN111989332 A CN 111989332A
Authority
CN
China
Prior art keywords
cancer
alkyl
amino
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980022306.8A
Other languages
English (en)
Other versions
CN111989332B (zh
Inventor
邓永奇
孙健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaifu Suzhou Biomedical Co ltd
Original Assignee
Kaifu Suzhou Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaifu Suzhou Biomedical Co ltd filed Critical Kaifu Suzhou Biomedical Co ltd
Publication of CN111989332A publication Critical patent/CN111989332A/zh
Application granted granted Critical
Publication of CN111989332B publication Critical patent/CN111989332B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

涉及作为CDK抑制剂的大环化合物、其制备方法及其在医药上的应用。具体而言，涉及一种通式(I)所示的新的大环化合物、其制备方法及含有该化合物的药物组合物以及其作为治疗剂，特别是作为CDK抑制剂的用途以及用于治疗癌症、炎症、病毒感染、心脏肥大或HIV的用途，其中通式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980022306.8A 2018-12-19 2019-12-11 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 Active CN111989332B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811558752 2018-12-19
CN2018115587524 2018-12-19
PCT/CN2019/124575 WO2020125513A1 (zh) 2018-12-19 2019-12-11 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN111989332A true CN111989332A (zh) 2020-11-24
CN111989332B CN111989332B (zh) 2022-07-26

Family

ID=71100402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022306.8A Active CN111989332B (zh) 2018-12-19 2019-12-11 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用

Country Status (7)

Country Link
US (1) US20220017520A1 (zh)
EP (1) EP3865488A4 (zh)
JP (1) JP2022517723A (zh)
KR (1) KR20210105375A (zh)
CN (1) CN111989332B (zh)
TW (1) TW202035422A (zh)
WO (1) WO2020125513A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113603708A (zh) * 2021-07-27 2021-11-05 中国药科大学 一种具有大环骨架结构的新型cdk9抑制剂的制备及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510471A (zh) * 2022-07-29 2024-02-06 江苏天士力帝益药业有限公司 一种阿贝西利的合成方法
WO2024046443A1 (en) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Macrocyclic compounds as selective cdk inhibitors
CN116003419B (zh) * 2022-11-18 2023-10-13 北京师范大学 大环化合物及制备方法
WO2024152995A1 (zh) * 2023-01-20 2024-07-25 上海海量医药科技有限公司 一种大环类细胞周期蛋白抑制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058927A1 (en) * 2005-11-11 2007-05-24 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2018177899A1 (en) * 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101499594B1 (ko) * 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
JP5931850B2 (ja) * 2010-05-27 2016-06-08 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド・ア・ボディ・コーポレイトＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｏｌｏｒａｄｏ Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ ヒストンデアセチラーゼの阻害剤として有用な大環状化合物
CN105916848B (zh) 2013-12-31 2018-01-09 山东轩竹医药科技有限公司 激酶抑制剂及其用途
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
SG11201709837RA (en) 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
JP6691958B2 (ja) * 2016-05-20 2020-05-13 オンキュアー，インコーポレイテッド ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058927A1 (en) * 2005-11-11 2007-05-24 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2018177899A1 (en) * 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113603708A (zh) * 2021-07-27 2021-11-05 中国药科大学 一种具有大环骨架结构的新型cdk9抑制剂的制备及其应用
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用

Also Published As

Publication number Publication date
WO2020125513A1 (zh) 2020-06-25
CN111989332B (zh) 2022-07-26
EP3865488A4 (en) 2021-12-22
EP3865488A1 (en) 2021-08-18
JP2022517723A (ja) 2022-03-10
TW202035422A (zh) 2020-10-01
US20220017520A1 (en) 2022-01-20
KR20210105375A (ko) 2021-08-26

Similar Documents

Publication Publication Date Title
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP7084918B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
US10112950B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US20230286981A1 (en) Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
EP2945623B1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
US9758526B2 (en) Quinoline-substituted compound
TW201825472A (zh) 新穎化合物類
US20200385394A1 (en) 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES
US20220259235A1 (en) EGFR Inhibitor, Composition, and Preparation Method Therefor
CN114057771B (zh) 大环化合物及其制备方法和应用
US20180170947A1 (en) Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
JP2008505084A (ja) フラノピリミジン
JP2008507534A (ja) フラノピリジン誘導体および使用方法
JP2019500389A (ja) 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
US20170137427A1 (en) Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
US20150344480A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
EP3134405B1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
US20240279224A1 (en) Quinolines and azaquinolines as inhibitors of cd38
CN116670127A (zh) Egfr抑制剂及其组合物和用途
CN112513037A (zh) 用作fgfr4抑制剂的稠环衍生物
CN110407854B (zh) 新的四环化合物
EP4310081A1 (en) Ctla-4 small molecule degradation agent and application thereof
CN116635390A (zh) 作为血清素1b受体调节剂的强效和选择性化合物
CN117136052A (zh) Cdk抑制剂和其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 215000 unit 508, B2 / F, phase I, biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province

Applicant after: Kaifu (Suzhou) biomedical Co.,Ltd.

Address before: R2008, unit 201, B6 / F, phase I project of biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province, 215000

Applicant before: Kaifu (Suzhou) biomedical Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant